In Phenylketonuria the main aim of first-line therapy is
## **Core Concept**
Phenylketonuria (PKU) is a genetic disorder characterized by the inability to break down the amino acid phenylalanine (Phe), due to a deficiency in the enzyme **phenylalanine hydroxylase**. This leads to the accumulation of Phe in the body, which can cause intellectual disability and other serious health problems if not treated. The primary goal of treatment is to reduce Phe levels.
## **Why the Correct Answer is Right**
The main aim of first-line therapy in PKU is to reduce the levels of phenylalanine in the blood to prevent its toxic effects on the brain and other organs. This is primarily achieved through a strict dietary regimen that limits the intake of phenylalanine. The diet involves avoiding foods high in protein (since Phe is an amino acid found in many proteins) and using special low-protein foods and formulas that are Phe-free or low in Phe. By controlling Phe levels, individuals with PKU can prevent intellectual disability and other complications associated with the disorder.
## **Why Each Wrong Option is Incorrect**
- **Option A:** While enzyme replacement or supplementation might seem like a plausible treatment, it's not the first-line therapy for PKU. The primary treatment does not involve administering the deficient enzyme directly but rather limiting the substrate (Phe) for the enzyme.
- **Option B:** This option might involve other treatments or management strategies that are not the primary approach. For instance, tetrahydrobiopterin (BH4) supplementation is used in some cases of PKU, particularly in those responsive to BH4, but it's not the mainstay of treatment for all PKU patients.
- **Option C:** This could potentially refer to other therapeutic approaches or adjunctive treatments but does not represent the first-line therapy.
## **Clinical Pearl / High-Yield Fact**
A crucial point to remember is that early diagnosis and strict adherence to a low-Phe diet can significantly improve outcomes in PKU patients. In some cases, patients may also benefit from **tetrahydrobiopterin (BH4) therapy** if they are responsive, but this does not replace dietary control as the first-line approach.
## **Correct Answer:** . Restrict Phe intake